Effect of Intraperitoneally Injection of Different Doses of Lovastatin on Pain and Inflammatory Response Induced by Formalin in Mice by Khayatnouri Mirhadi
American Journal of Animal and Veterinary Sciences 6 (4): 160-165, 2011 
ISSN 1557-4555 
© 2011 K. Mirhadi et al., This open access article is distributed under a Creative Commons Attribution  
(CC-BY) 3.0 license 
160 
 
Effect of Intraperitoneally Injection of Different Doses of  
Lovastatin on Pain and Inflammatory Response Induced by Formalin in Mice 
 
Khayatnouri Mirhadi 
Department of Pharmacology, Tabriz Branch, Islamic Azad University, Tabriz, Iran 
 
Abstract:  Problem  statement:  The  3-Hydroxy-3-Methyl  Glutaryl-CoA  (HMG-CoA)  reductase 
inhibitors (statins) have been unequivocally shown to reduce cardiovascular morbidity and mortality. Their 
lipid-lowering actions are by reversible and competitive inhibition of the enzyme HMG-CoA reductase, a 
precursor of cholesterol. It has been suggested that statins appear to have therapeutic benefits in diseases that 
are unrelated to elevated serum cholesterol levels, such as pain and inflammatory. The aim of this study was 
to  determination  the  effect  of  intraperitoneally  injection  of  different  doses  of  lovastatin  on  pain  and 
inflammatory  response  induced  by  formalin  in  mice.  Approach:  Mice  were  divided  into  9  groups 
randomly:  the  first  group  received  saline  normal  (ip)  (saline  group);  the  second  group  received 
Carboxymethylcellulose  (CMC)  0.5%  (ip)  (vehicle  group)  and  the  next  groups  received  respectively 
different doses of lovastatin (1, 5, 10, 20, 40, 80 and 100 mg kg daily
-1) for 4 days (ip) before formalin test. 
After intrapawly injection of formalin, the time of hind paw biting and licking time measured in 5 min 
interval for an hour. Results: Results showed that formalin induces biphasic pain response (the first phase: 
0-5 min and the second phase 15-40 min after injection). Intraperitoneal injection of lovastatin showed 
significant (p<0.05) decrease of pain responses in the first and the second phase in a dose dependently 
manner. Conclusion: According to our results, lovastatin has analgesic and anti-inflammatory effects on 
mice. Nevertheless, new studies must be carried out in order to determine the beneficial effects of statins in 
treatment of pain and inflammatory. 
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INTRODUCTION 
 
  Pain is a percept consisting of initial nociception 
followed by a slower but integrated emotional phase. 
Nociception is the neural recognition of a potentially 
injurious physical or chemical stimulus. Pain responses 
occur only after centralized processing and elicitation 
of an emotional output to the nociceptive input. Long-
term painful stimuli may enhance sensitivity in some 
animals  and  humans  and  habituate  others.  Acute 
centrally  processed  pain  can  be  recognized  in 
animals  by  behavioral  changes  (Kamerling,  1993; 
Ley  and  Livingston,  1990).  The  inflammatory 
response  is  an  attempt  by  the  body  to  restore  and 
maintain homeostasis after injury or infection and is 
an integral part of body defense. For the survival of 
the host, inflammation is a necessary and beneficial 
process  but  chronic  inflammation  can  cause  harm 
(Beutler, 2003). Soluble mediators such as Nitric Oxide 
(NO),  Tumor  Necrosis  Factor-α  (TNF-α)  and 
interleukins usually play a role in controlling important 
functions  such  as  the  regulation  of  blood  pressure, 
platelet  aggregation  and  body  temperature  (Funk, 
2001).  Under  pathologically  inflammatory  conditions, 
however, the production of these molecules promotes 
events ranging from increased leukocyte infiltration and 
vascular permeability to organ failure (Acquisto et al., 
2002).  The  selective  inhibition  of  these  and  other 
inflammatory activities remains an important goal for 
the effective treatment of inflammation. 
  The  3-Hydroxy-3-Methyl  Glutaryl-CoA  (HMG-
CoA)  reductase  inhibitors  (statins)  have  been 
unequivocally  shown  to  reduce  cardiovascular 
morbidity and mortality (SSSSG, 1994; Shepherd et al., 
1995).  Statins  are  among  the  most  widely  used 
prescription drugs and exert their lipid-lowering actions 
by reversible and competitive inhibition of the enzyme 
3-hydroxy-3-methyl-glutaryl-CoA  reductase  (HMG-
CoA reductase), the rate-limiting step in the conversion 
of  3-hydroxy-3-methylglutaryl-coenzyme  A  (HMG-
CoA)  to  mevalonate,  a  precursor  of  cholesterol 
(McTaggart  et  al.,  2001).  It  has  been  suggested  that 
statins appear to have therapeutic benefits in diseases 
that are unrelated to elevated serum cholesterol levels, American J. Animal & Vet. Sci., 6 (4): 160-165, 2011 
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such  as  rheumatologic  diseases  and  ischemic  stroke 
(McCarey et al., 2004). Statins are also known for their 
pleiotropic effects, which are independent of their lipid-
lowering properties. Among the effects of statins, the 
most  relevant  are  anti  atherosclerotic  and  anti-
inflammatory  actions,  improvement  of  endothelial 
dysfunction,  anti-thrombosis  and  anti-oxidant  actions, 
prevention  of  Alzheimer’s  disease  and  antineoplasic 
actions (Gonçalves et al., 2011). Although such clinical 
benefits are mediated in part through lipid modulation, 
recent  studies  demonstrate  broader  properties  for 
statins,  particularly  in  modifying  inflammatory 
pathways  ongoing  within  the  atherosclerotic  lesion 
(Ross,  1999).  Statins  might  exert  beneficial  effects 
beyond  cholesterol  reduction;  include  improving 
endothelial function, decreasing vascular inflammation, 
inhibiting  smooth-muscle  proliferation  and 
immunomodulation. Most of these effects are mediated 
through  inhibition  of  isoprenoid  synthesis,  with 
subsequent  effects  on  multiple  downstream  signaling 
pathways  (Wang  et  al.,  2008).  Immunomodulatory 
activities of statins could be beneficial in treatment of 
various  inflammatory  conditions.  This  observation 
prompted subsequent in vitro studies that demonstrated 
that  statins  interfered  with  production  of  several 
important  proinflammatory  mediators  (Pahan  et  al., 
1997).  Most  of  the  reports  point  to  the  anti-
inflammatory  effects  of  statins  focused  on 
cardiovascular  diseases  and  atherosclerosis  and  about 
orally  administration  of  these  drugs  (Garjani  et  al., 
2008; Gonçalves et al., 2011; Kumar et al., 2010). Also 
studies showed that statins has a biphasic pro- and anti-
inflammatory  effect  (Garjani  et  al.,  2008).  Therefore 
the aim of this study was to determination of the effect 
of  intraperitoneally  injection  of  different  doses  of 
lovastatin on pain and inflammatory response induced 
by formalin in mice. 
 
MATERIALS AND METHODS 
 
Animals:  Experiments  were  performed  on  22-25  g 
adult NMRI male mice in their 8-9 week (n = 8 for each 
group), purchased from Razi Institute (Iran). Animals 
were  housed  8  per  cage  in  the  Animal  House  of 
Veterinary  Faculty  of  Tabriz  Branch,  Islamic  Azad 
University  in  a  temperature  (20-22°C)  and  humidity 
(50±10%)  controlled  environment  under  a  12  h 
light/dark  cycle  (lights  on  at  7  am).  Food  and  water 
were available ad libitum. This study was performed in 
accordance  with  the  Guide  for  the  Care  and  Use  of 
Laboratory  Animals  of  Research  affairs  of  Tabriz 
University of Medical Sciences, Tabriz-Iran. All efforts 
were made to minimize the number of animals which 
were  used  and  their  suffering  degree.  Animals  were 
divided into 9 groups randomly: the first group received 
saline  normal  (ip)  (saline  group);  the  second  group 
received  Carboxymethylcellulose  (CMC)  0.5%  (ip) 
(vehicle  group)  and  the  next  groups  received 
respectively different doses of lovastatin (1, 5, 10, 20, 
40, 80 and 100 mg kg daily
-1) for 4 days (ip) before 
formalin test. 
 
Chemicals:  Formalin  was  purchased  from  Merck 
Company.  Lovastatin  was  provided  from  Merck 
Pharmaceuticals. All other reagents were of analytical 
grade. Lovastatin was prepared by being dissolved in 
0.5% Carboxy Methyl Cellulose (CMC) and the vehicle 
group was given an equal volume of vehicle. 
 
Formalin test: Behavioral experiments were done in a 
quiet, temperature-controlled (20-22°C) room between 
10 am and 4 pm. Formalin test was preformed based on 
Dubission and Dennis method (Modified formalin test: 
characteristic  biphasic  pain  response).  After  being 
weighted,  the  animals  were  placed  in  observation 
container  for  15  min  to  get  used  to  the  new 
environment and then 20  L of attenuated formalin 
(5%)  was  injected  in  hind  paw  skin  (intradermal 
route)  with  insulin  syringe  in  restrainer.  After 
injection,  animals  were  returned  to  observation 
container immediately and were viewed. The time of 
hind paw biting and licking time measured in 5 min 
interval for an 20 h. 
 
Data  analysis:  Group  data  are  presented  as  mean  ± 
SEM and analyzed statistically using student test. Time 
course  data  were  analyzed  using  one-way  ANOVA 
followed  by  Tukey’s  post  hoc  test.  The  level  for 
statistical significance was set at a p<0.05. 
 
RESULTS 
 
  Formalin  injection  to  hind  paw  after  intra 
peritoneal  injection  of  normal  saline  induced 
significant (p<0.05) pain response (Time of licking 
and biting of injected paw) in the first, the fourth, the 
fifth,  the  sixth,  the  seventh  and  the  8-5  min  in 
comparison with other 5 min (Fig. 1), as results show 
formalin  induces  biphasic  pain  response  (the  first 
phase: 0-5 min and the second phase 15-40 min after 
injection).  
  In  vehicle  group,  CMC  have  not  shown 
significant change on formalin induced biphasic pain 
response  compared  with  saline  group  (Fig.  1). 
Intraperitoneal injection of lovastatin before hind paw 
injection  of  formalin  showed  significant  (p<0.05) 
decrease of pain responses (Time of licking and biting 
of injected paw), in the first phase (1-5 min) and the 
second phase (fourth, fifth, sixth, seventh and the 8-5 
min)  in  a  dose  dependently  manner  compared  with 
saline and vehicle groups (Fig. 1). American J. Animal & Vet. Sci., 6 (4): 160-165, 2011 
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Fig. 1: Time course of paw licking and biting response 
to formalin injection. Effect of intraperitoneally 
administration of different doses of lovastatin on 
first and second phase of pain responses. Each 
line represents mean ± SEM of 8 mice. *p<0.05 
compared with saline and vehicle groups 
 
DISCUSSION 
 
  Formalin test has two phases; early or first phase 
(neurogenic  pain)  and  delayed  or  second  phase 
(inflammatory pain). It seems that early phase induced 
by  C  fiber  activation  and  peripheral  stimulates.  But 
inflammatory reactions in peripheral tissues and action 
change in dorsal root of spine are the main reasons of 
delayed phase. The main reason of pain in the second 
phase is the inflammatory reactions (Abad et al., 2011). 
Results  of  present  study  have  shown  that  lovastatin 
decreased pain and inflammatory response in formalin 
test, in a dose dependently manner, in both neurogenic 
and inflammatory origin. 
  Anti-nociceptive and anti-inflammatory effects of 
statins  have  been  shown  in  different  experimental 
animal models of pain and inflammatory and clinical 
studies,  but  effects  of  intraperitoneally  injection  of 
different  doses  of  statins  have  not  shown.  Studies 
showed that lovastatin has a potent anti-inflammatory 
activity since it inhibits carrageenan-induced peritonitis 
and paw edema. Although these findings are consistent 
with studies showing these effects of statins in many 
inflammation  models,  most of  them  were  carried out 
with  other  statins,  mainly  simvastatin  (Dantas  et  al., 
2010; Massaro et al., 2010; Nezic et al., 2009). Studies 
demonstrate that simvastatin provides a highly effective 
therapy  in  treating  murine  Collagen-Induced  Arthritis 
(CIA),  a  surrogate  model  for  human  Rheumatoid 
Arthritis  (RA).  Previous  studies  of  thioglycolate 
peritonitis  or  carrageenan-induced  paw  pad 
inflammation  suggested  that  statins  modify  acute 
inflammation (Sparrow et al., 2001; Weitz-Schmidt et 
al.,  2001).  Histological  examination  of  paw  lesions 
confirmed  that  simvastatin  inhibits  the  acute 
inflammation  induced  by  carrageenan.  These 
investigators  concluded  that  simvastatin  reduced  the 
polymorphonuclear  leukocyte  infiltration,  dose-
dependently  and  similarly  to  indomethacin  (Nezic  et 
al., 2009). Furthermore, atorvastatin was shown to be 
even more effective than diclofenac in decreasing joint 
inflammation  and  hyperalgesia  in  a  rat  model  of 
arthritis (Mandosi et al., 2010) and in reducing TNF-α 
production  in  lipopolysaccharideactivated  monocytes 
from  diabetic  patients  (Trocha  et  al.,  2010).  In  both 
experimental  and  clinical  studies,  statins  have  been 
shown  to  suppress  acute  and  chronic  inflammation. 
Their anti-inflammatory effect is brought about through 
inhibition  of oedema  formation, leukocyte-endothelial 
adhesion and production of inflammatory mediators 
(Kumar et al., 2010). Besides, they have been shown 
to afford protection in various experimental models 
of  arthritis  by  reducing  articular  inflammation, 
preventing  bone  loss  and  preserving  bone  mineral 
density (Funk et al., 2008; Yamagata et al., 2007). 
Another statin, simvastatin, was reported to prevent 
the  increase  of  iNOS  concentration  after 
ischemia/reperfusion injury in the rat liver. As well as 
in those studies, these effects of statins were mediated, 
at least in part, by the reduction of cytokines such as 
TNF-α  and  by  the  decrease  of  iNOS  production. 
Besides  being  involved  in  inflammatory  processes, 
iNOS  has  also  been  implicated  in  neuropathic  pain. 
Hasegawa et al. (2003) reported that 6 weeks treatment 
with cerivastatin (1mg kg d
-1) significantly attenuated 
the expression of pro-inflammatory cytokine interleukin 
1b (IL-1b) in Dalt salt sensitive rats with left ventricular 
hypertrophy and chronic heart failure (Hasegawa et al., 
2003).  Lovastatin  partially  suppressed  acute 
Experimental Autoimmune Encephalomyelitis (EAE) in 
rats (Stanislaus et al., 1999). Atorvastatin, one of the 
longer  acting  and  clinically  used  statins,  has  been 
demonstrated to attenuate inflammatory hyperalgesia in 
a rat model of monoarticular arthritis. Atorvastatin has 
been  documented  to  relieve  hyperalgesia  and  to 
improve  joint  functions  in  the  arthritic  rats  (Wahane 
and Kumar, 2010). Barsante et al. (2005) have reported 
anti-inflammatory and anti-hypernociceptive effects of 
atorvastatin  in  chronic  arthritis  induced  by 
immunization  of  rats  with  adjuvant  (Barsante  et  al., 
2005).  Clinical  studies  such  as  the  West  of  Scotland 
Coronary Prevention Study (WOSCOPS), a randomized 
placebo  controlled  study,  provided  evidence  that  the 
anti-inflammatory  effect  of  pravastatin  treatment  is American J. Animal & Vet. Sci., 6 (4): 160-165, 2011 
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probably  independent  of  changes  in  the  lipid  profile 
(WOSCOPS, 1998). Statins have been used to reduce 
inflammation,  tame  immune  cell  activation,  or  arrest 
degenerative  processes.  Because  of  their  widespread 
use  and  long-term  safety  record,  some  physicians 
prescribe statin therapy for non approved indications. A 
number of case reports describe the dramatic effects of 
statins  added  to  standard  therapies,  but  beneficial 
effects need to be confirmed in controlled studies. For 
example,  in  three  patients  with  lupus 
glomerulonephritis  who  were  not  responding  to  the 
standard of therapy, adding high doses of simvastatin 
brought about a dramatic reduction in disease activity. 
There are randomized, placebo controlled studies, but 
two issues cloud the results: the particular statin used 
and the dose. Clearly the anti-inflammatory properties 
of  statins  vary,  whereas  the  cholesterol-lowering 
properties are similar. Six clinically used statins were 
examined  in  vitro  for  their  ability  to  affect  NF-kB, 
phosphorylation of IkB and activation of tissue factor, 
the  first  step  in  coagulation.  There  was  a  distinct 
difference between the statins: cerivastatin, atorvastatin 
and simvastatin were more effective in reducing these 
parameters  than  fluvastatin,  lovastatin,  or  pravastatin 
(Dinarello  2010).  Also,  other  clinical  studies 
demonstrated  that  in  a  small  group  of  patients  with 
Heart Failure (HF) and normal cholesterol levels that 
administration of atorvastatin 10 mg for 4 weeks led to 
a significant reduction in IL-6, TNF-alpha and VCAM-
1  levels,  that  confirmed  that  the  anti-inflammatory 
action  of  statin  in  this  high  risk  group  of  patients 
(Tousoulis et al., 2005). Nevertheless, there seems to be 
no dearth of case reports and small uncontrolled trials 
that  show  the  benefits  of  statins  for  reducing 
inflammation. In the case of rheumatoid arthritis where 
the  anti-inflammatory  effects  of  blocking  cytokines 
have been shown repeatedly, there have been more than 
ten trials of statins resulting in a moderate reduction in 
joint inflammation associated with a fall in C-Reactive 
Protein  (CRP)  and  red  cell  sedimentation  rate  and 
decreased  cytokine  production  by  circulating 
monocytes.  As  many  patients  with  long-standing 
rheumatoid  arthritis  are  also  at  high  risk  for 
cardiovascular  disease,  adding  statin  therapy  to  the 
standard of care is highly cost effective. Adding statins 
to the regimen of cyclosporine and sirolimus for kidney 
transplant patients lowered the rate of organ rejection. 
In patients with relapsing-remitting multiple sclerosis, 
statin  therapy  for  6  months  significantly  lowered  the 
number  of  brain  lesions  detected  by  gadolinium,  an 
established marker of disease activity. Examination of 
peripheral blood cells revealed no suppression in T 
cell  responses  but  did  reveal  an  increase  in 
production of IL-10, an anti-inflammatory cytokine 
(Dinarello, 2010). Nevertheless, new and completely 
studies must be carried out in order to determine in 
more detail the beneficial actions of statins regarding 
the reduction of pro-inflammatory mediators. 
 
CONCLUSION 
 
  According to our results, lovastatin has analgesic 
and anti-inflammatory effects on mice. Nevertheless, 
new studies must be carried out in order to determine 
the beneficial effects of statins in treatment of pain 
and inflammatory. 
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